Learn more about customizing treatment for a wide variety of your acne patients       SOLODYN® 1 mg/kg SIGNIFICANTLY REDUCED INFLAMMATORY LESIONS IN DOSE-RANGING AND PIVOTAL STUDIES   How can you help a wide variety of patients experience clearer skin, while still considering their individual needs? With customized dosing that doesn’t compromise efficacy:   • In a phase 2 study (N=233), SOLODYN reduced inflammatory lesions by 56.8% vs 39.4% with placebo, when administered once daily (P=0.015)1,2*   • In 2 phase 3 studies (N=451 and N=473), SOLODYN reduced inflammatory lesions by 43.1% and 45.8% vs placebo (31.7% and 30.8% with placebo, P=0.001 and P<0.001, respectively)1,2 To learn more about how the customized dosing of SOLODYN has been proven effective in the clinical setting, please click here.   Stay tuned for information on the science behind SOLODYN.   Indication and Usage   SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.     SOLODYN did not demonstrate any effect on non-inflammatory acne lesions. Safety of SOLODYN has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SOLODYN should be used only as indicated.   Important Safety Information for SOLODYN Tablets   • This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines   • MINOCYCLINE, LIKE OTHER TETRACYCLINE-CLASS DRUGS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. Should not be used during pregnancy or by individuals of either gender who are attempting to conceive a child; concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.   • TETRACYCLINE DRUGS SHOULD NOT BE USED DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY AND UP TO 8 YEARS OF AGE) AS THEY MAY CAUSE PERMANENT DISCOLORATION OF TEETH.   • Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening; therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents   • Dose adjustments may be necessary in patients with renal impairment to avoid liver toxicity   • Central nervous system side effects, including light-headedness, dizziness, and vertigo, have been reported with minocycline therapy   • Pseudotumor cerebri (benign intracranial hypertension) and autoimmune syndromes have been associated with the use of tetracyclines   • Cases of anaphylaxis, serious skin reactions, erythema multiforme, and drug rash with eosinophilia and systemic symptoms have been reported postmarketing with minocycline use. Discontinue SOLODYN immediately if symptoms occur. In rare cases, photosensitivity has been reported.   • The most commonly observed adverse reactions are headache, fatigue, dizziness, and pruritus   Click here for Prescribing Information.       * In a phase 2 dose-response study of 233 subjects with the 45-mg, 90-mg, and 135-mg strengths, 1 mg/kg/day extended-release SOLODYN Tablets provided statistically significant inflammatory lesion reduction vs placebo (n=114, 56.8% vs 39.4%, P=0.015). Patients entering the phase 2 study had 20 to 100 inflammatory facial lesions; those entering the phase 3 studies had 25 to 75.1     References: 1. Data on file, Valeant Pharmaceuticals Corporation. 2. SOLODYN Tablets Package Insert. Scottsdale, AZ: Medicis, The Dermatology Company; October 2013.   You have the right to opt out of receiving unsolicited advertisements by email. You may contact us with your opt-out request, along with the email to which your request relates, by telephone at 1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 30 days of receipt. Please be sure to indicate the email address to which your request relates and reason for opt-out.   Valeant Pharmaceuticals International, Inc. 400 Somerset Corp. Blvd. Bridgewater, NJ 08807 USA Except as otherwise indicated, all product names, slogans, and other marks are trademarks of the Valeant family of companies.   ©2014 Valeant Pharmaceuticals North America LLC.   DM/SDN/14/0006(1)